Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

High-Dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

This study has been completed.
Information provided by:
Foundation for Liver Research Identifier:
First received: September 27, 2006
Last updated: July 31, 2007
Last verified: July 2007

The purpose of this study is to compare pharmacokinetics by IFN assays and pharmacodynamics by patient's HCVRNA suppression of 360 mug peginterferon QW, 9 MU interferon daily or 4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment. Comparison of virological breakthrough/relapse rate after dose adjustments and sustained virological response rate will be assessed by the type of induction.

Condition Intervention Phase
Hepatitis C
Drug: Peginterferon alfa-2a
Drug: Interferon alfa-2a
Drug: Ribavirin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Comparative Study of High-Dose Interferon Alfa-2a and Pegylated Interferon Alfa-2a for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

Resource links provided by NLM:

Further study details as provided by Foundation for Liver Research:

Primary Outcome Measures:
  • To compare pharmacokinetics by IFN assays and pharmacodynamics by patient's HCV RNA suppression of 360 mug peginterferon alfa-2a QW, 9 MU interferon alfa-2a daily or 4,5 interferon alfa-2a daily in combination with 180 mug peginterferon alfa-2a QW in the

Secondary Outcome Measures:
  • To compare the virological breakthrough/relapse rate after dose adjustments (at 4,24,72) weeks.
  • To compare the sustained virological response rate at 24 weeks after end of treatment.

Enrollment: 33
Study Start Date: February 2003
Study Completion Date: July 2006

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • chronic hepatitis C
  • detectable serum HCV-RNA
  • elevated serum ALT activity documented on at least two occasions within the past 12 months, with at least one during the 90 day screening period preceding the initiation of test drug dosing
  • liver biopsy findings (during screening or within previous 12 months) consistent with active fibrosis (haemophiliacs are excluded from biopsies)
  • compensated liver disease (Child-Pugh Grade A clinical classification)
  • negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
  • all fertile males and females receiving ribavirin and their fertile or potentially fertile partners must be advised to use two forms of effective contraception (combined) during treatment and during the 6 months after end of treatment

Exclusion Criteria:

  • history or other evidence of severe illness, malignancy or any other condition which would make the patient, in the opinion of the investigator, unsuitable for the study
  • women with ongoing pregnancy or breast feeding
  • therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) <3 months prior to the first dose of study drug
  • any investigational drug <6 weeks prior to the first dose of study drug positive test at screening for HBsAg, anti-HIV Ab history or other evidence of bleeding from esophageal varices, ascites, or other conditions consistent with decompensated liver disease (Child-Pugh Grade B or C clinical classification)
  • Signs or symptoms of hepatocellular carcinoma
  • history or other strong evidence of a medical condition associated with chronic liver disease other than HCV (e.g., primary hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures
  • Hb <7.5 mmol/l in women or <8.6 mmol/l in men at screening
  • any patient with an increased baseline risk for anaemia (e.g. thalassemia, spherocytosis, etc) or for whom anaemia would be medically problematic neutrophil count <1500 cells/mm3 or platelet count <80,000 cells/mm3 at screening
  • serum creatinine level >1.5 times the upper limit of normal at screening
  • history of severe psychiatric disease, especially depression
  • history of a severe seizure disorder or current anticonvulsant use
  • history of immunologically mediated disease
  • history or other evidence of chronic pulmonary disease associated with functional limitation
  • history of severe allergies
  • history of symptomatic and/or significant cardiovascular disease
  • poorly controlled diabetes mellitus
  • history of major organ transplantation with an existing functional graft
  • hyper- or hypothyroidism
  • evidence of severe retinopathy
  • evidence of drug abuse (including excessive alcohol consumption within one year before study entry
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00381953

Erasmus Medical Center
Rotterdam, Netherlands, 3015 CE
Sponsors and Collaborators
Foundation for Liver Research
Principal Investigator: Rob J. de Knegt, MD, PhD Erasmus Medical Center
  More Information

No publications provided Identifier: NCT00381953     History of Changes
Other Study ID Numbers: HCV02-01
Study First Received: September 27, 2006
Last Updated: July 31, 2007
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Additional relevant MeSH terms:
Peginterferon alfa-2a
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on March 01, 2015